Delving into the Latest Updates on Hydrochlorothiazide/Moexipril Hydrochloride with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Uniretic

Target

ACE x NCC

Action

inhibitors

Mechanism

ACE inhibitors(Angiotensin-converting enzyme inhibitors), NCC inhibitors(Thiazide-sensitive sodium-chloride cotransporter inhibitors)

Therapeutic Areas

Cardiovascular Diseases

Active Indication-

Inactive Indication

Hypertension

Originator Organization

UCB SA

Active Organization-

Inactive Organization

UCB, Inc.

License Organization-

Drug Highest PhaseWithdrawn

First Approval Date

United States (27 Jun 1997),

Hypertension

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC27H35ClN2O7

InChIKeyJXRAXHBVZQZSIC-JKVLGAQCSA-N

CAS Registry82586-52-5

View All Structures (2)

The objective of this study is to compare the relative bioavailability of Moexipril HCl/hydrochlorothiazide 15/25 mg tablets (manufactured and distributed by TEVA Pharmaceuticals USA) with that of UNIRETIC® 15/25 mg tablets (Schwartz Pharma) in healthy, adult non-smoking subjects under fasting conditions.

Start Date01 Oct 2003

Sponsor / Collaborator

Teva Pharmaceuticals USA, Inc.

NCT00834067

/ CompletedPhase 1

A Relative Bioavailability Study of Moexipril HCl/Hydrochlorothiazide 15/25 mg Tablets Under Non-Fasting Conditions

The objective of this study is to compare the relative bioavailability of moexipril HCl/ hydrochlorothiazide 15/25 mg tablets (manufactured and distributed by TEVA Pharmaceuticals USA) with that of UNIRETIC® 15/25 mg tablets (Schwartz Pharma) in healthy, adult, non-smoking subjects under non-fasting conditions.

Start Date01 Oct 2003

Sponsor / Collaborator

Teva Pharmaceuticals USA, Inc.

NCT00990301

/ CompletedPhase 1

A Study to Compare the Relative Bioavailability of Moexipril HCl/Hydrochlorothiazide 15mg/25mg Tablets (Paddock Laboratories, Inc) and Uniretic® 15mg/25mg Tablets (Schwarz Pharma)(Moexipril HCl/Hydrochlorothiazide) in Healthy Adult Volunteers Under Fasting Conditions.

The purpose of this study was to evaluate the relative bioavailability of Paddock Laboratories, Inc.'s test formulation of Moexipril/ Hydrochlorothiazide 15mg/25mg tablets with a reference formulation Uniretic®(Moexipril/ Hydrochlorothiazide) 15mg/25mg tablets, under fasting conditions.

Start Date-

Sponsor / Collaborator

Paddock Laboratories, Inc.

100 Clinical Results associated with Hydrochlorothiazide/Moexipril Hydrochloride

Login to view more data

100 Translational Medicine associated with Hydrochlorothiazide/Moexipril Hydrochloride

Login to view more data

100 Patents (Medical) associated with Hydrochlorothiazide/Moexipril Hydrochloride

Login to view more data

100 Deals associated with Hydrochlorothiazide/Moexipril Hydrochloride

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D10281	-	C09BA13	-

R&D Status

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Hypertension	United States	UCB, Inc.	27 Jun 1997

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT00835042 (CTgov)	Phase 1	-	60	Moexipril HCl+HCTZ (Test (Moexipril HCl/HCTZ))	nlpvdfdsst(wwpehwxbcq) = ovgshacvzm zpboinbxat (yabqajyyxu, 15.761) View more	-	18 Aug 2009
				Uniretic (Reference (Uniretic®))	nlpvdfdsst(wwpehwxbcq) = rattzhsdyq zpboinbxat (yabqajyyxu, 17.4) View more
NCT00834067 (CTgov)	Phase 1	-	60	Moexipril HCl+HCTZ (Test (Moexipril HCl/HCTZ))	girkoywbrg(pacmgimimt) = cerbonvphw myhksycggi (xshztfqmla, 6.706) View more	-	18 Aug 2009
				Uniretic (Reference (Uniretic®))	girkoywbrg(pacmgimimt) = sxqbdgyfwr myhksycggi (xshztfqmla, 6.018) View more